PLAAT3

Summary

PLAAT3 (phospholipase A and acyltransferase 3, HGNC:17825) is a protein-coding gene on chromosome 11q12.3-q13.1, encoding Phospholipase A and acyltransferase 3 (P53816). Exhibits both phospholipase A1/2 and acyltransferase activities.

Enables N-acyltransferase activity; lipid binding activity; and phospholipase activity. Involved in N-acylphosphatidylethanolamine metabolic process. Predicted to be located in several cellular components, including lysosome; nuclear envelope; and peroxisome. Predicted to be active in cytoplasm. Biomarker of seminoma.

Source: NCBI Gene 11145 — RefSeq curated summary.

At a glance

• Gene–disease (curated): lipodystrophy, familial partial, type 9 (Strong, GenCC)
• Clinical variants (ClinVar): 51 total — 3 pathogenic, 1 likely-pathogenic
• Phenotypes (HPO): 49
• Druggable target: yes
• MANE Select transcript: NM_001128203

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:17825
Approved symbol	PLAAT3
Name	phospholipase A and acyltransferase 3
Location	11q12.3-q13.1
Locus type	gene with protein product
Status	Approved
Aliases	HREV107, H-REV107-1, HREV107-3, MGC118754., AdPLA, PLAAT-3
Ensembl gene	ENSG00000176485
Ensembl biotype	protein_coding
OMIM	613867
Entrez	11145

Gene structure

Transcript identifiers

Ensembl transcripts: 16 — 14 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000323646, ENST00000394613, ENST00000415826, ENST00000540943, ENST00000544269, ENST00000873643, ENST00000873644, ENST00000873645, ENST00000873646, ENST00000873647, ENST00000873648, ENST00000911543, ENST00000911544, ENST00000911545, ENST00000911546, ENST00000911547

RefSeq mRNA: 2 — MANE Select: NM_001128203 NM_001128203, NM_007069

CCDS: CCDS8047

Canonical transcript exons

ENST00000415826 — 5 exons

Exon	Start	End
ENSE00001671551	63614385	63614433
ENSE00001712076	63614000	63614068
ENSE00003575548	63598061	63598163
ENSE00003601992	63590100	63590368
ENSE00003909622	63574462	63575046

Expression profiles

Bgee: expression breadth ubiquitous, 287 present calls, max score 99.33.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 26.9610 / max 709.3708, expressed in 1545 samples.

FANTOM5 promoters (15 alternative TSS)

Promoter ID	TPM avg	Samples expressed
120318	11.0631	1457
120317	8.6588	1035
120319	1.8765	941
120312	1.4697	621
120313	0.9424	381
120314	0.7158	258
120311	0.6362	253
120316	0.4155	252
120309	0.2824	123
120310	0.2707	61

Top tissues by expression

293 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
C1 segment of cervical spinal cord	UBERON:0006469	99.33	gold quality
spinal cord	UBERON:0002240	99.01	gold quality
corpus callosum	UBERON:0002336	98.76	gold quality
adipose tissue	UBERON:0001013	98.51	gold quality
adipose tissue of abdominal region	UBERON:0007808	98.47	gold quality
tibial nerve	UBERON:0001323	98.44	gold quality
inferior vagus X ganglion	UBERON:0005363	98.43	gold quality
omental fat pad	UBERON:0010414	98.43	gold quality
left testis	UBERON:0004533	98.41	gold quality
peritoneum	UBERON:0002358	98.40	gold quality
right testis	UBERON:0004534	98.32	gold quality
subcutaneous adipose tissue	UBERON:0002190	98.21	gold quality
lateral globus pallidus	UBERON:0002476	98.16	gold quality
middle frontal gyrus	UBERON:0002702	98.10	gold quality
substantia nigra pars reticulata	UBERON:0001966	97.93	gold quality
apex of heart	UBERON:0002098	97.79	gold quality
putamen	UBERON:0001874	97.59	gold quality
globus pallidus	UBERON:0001875	97.59	gold quality
substantia nigra	UBERON:0002038	97.59	gold quality
connective tissue	UBERON:0002384	97.53	gold quality
midbrain	UBERON:0001891	97.49	gold quality
inferior olivary complex	UBERON:0002127	97.47	gold quality
subthalamic nucleus	UBERON:0001906	97.46	gold quality
amygdala	UBERON:0001876	97.40	gold quality
medial globus pallidus	UBERON:0002477	97.39	gold quality
heart left ventricle	UBERON:0002084	97.29	gold quality
hypothalamus	UBERON:0001898	97.23	gold quality
cardiac ventricle	UBERON:0002082	97.21	gold quality
right atrium auricular region	UBERON:0006631	97.13	gold quality
hindlimb stylopod muscle	UBERON:0004252	97.12	gold quality

Single-cell (SCXA)

Detected in 11 experiment(s), a significant marker in 10.

Experiment	Marker?	Max mean expression
E-MTAB-11121	yes	709.62
E-GEOD-134144	yes	34.64
E-MTAB-10287	yes	30.25
E-MTAB-8410	yes	21.90
E-MTAB-6701	yes	18.15
E-HCAD-1	yes	15.60
E-GEOD-84465	yes	12.13
E-MTAB-9388	yes	11.46
E-MTAB-6678	yes	9.17
E-MTAB-6524	no	286.05
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): ETS2, FOXC1, IRF1, PPARG, SP1, SP3, TP53

miRNA regulators (miRDB)

18 targeting PLAAT3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-1305	99.91	71.43	3443
HSA-MIR-345-3P	99.89	70.23	1421
HSA-MIR-6885-3P	99.75	70.36	3187
HSA-MIR-670-5P	99.67	69.94	1565
HSA-MIR-4743-3P	99.62	68.12	2095
HSA-MIR-3171	99.49	69.06	776
HSA-MIR-4652-3P	99.33	70.02	2742
HSA-MIR-223-5P	99.24	68.82	1206
HSA-MIR-26B-3P	98.71	67.49	1102
HSA-MIR-6830-3P	98.62	68.07	1760
HSA-MIR-581	98.39	67.42	835
HSA-MIR-4778-5P	97.96	68.06	1634
HSA-MIR-6787-3P	97.75	66.17	1233
HSA-MIR-6859-3P	97.26	64.69	428
HSA-MIR-1251-5P	95.78	64.10	374
HSA-MIR-4655-3P	82.43	62.92	60

Literature-anchored findings (GeneRIF, showing 20)

• Contact inhibition of growth and growth arrest caused by histone deacetylase inhibitors probably use the same mechanism to stimulate H-rev107 expression via histone acetylation in NIH3T3 cells (PMID:12054741)
• H-REV107-1 is deficient in its function as a tumor suppressor in non-small cell lung carcinomas. (PMID:17003497)
• Identification and functional characterization of adipose-specific phospholipase A2 (AdPLA) (PMID:18614531)
• AdPLA ablation increases lipolysis and prevents obesity induced by high-fat feeding or leptin deficiency. (PMID:19136964)
• role of PKC isoenzymes in PP2A and HRSL3(H-REV107-1) tumor suppressor-dependent cell death induction in ovarian carcinoma cell line; verified contribution to PP2A- and HRLS3-dependent apoptosis for PKCzeta suggesting a proapoptotic function of this kinase (PMID:20501645)
• Data show that acyl-modified forms of HRAS-like tumor suppressors HRASLS2 and HRASLS3 mimicking lipolytic activity of lecithin retinol acyltransferase LRAT. (PMID:22605381)
• an alternate mechanism for AdPLA in promoting adipose tissue lipolysis that is not contingent on the release of arachidonic acid and that is compatible with its combined PLA(1)/A(2) activity (PMID:22923616)
• Our study further suggests that the PLA/AT activity of H-rev107 may play an important role in H-rev107-mediated RAS suppression. (PMID:24884338)
• several mutant p53 proteins bind the Pla2g16 promoter at E26 transformation-specific (ETS) binding motifs and knockdown of ETS2 suppressed mutant p53 induction of Pla2g16. (PMID:25024203)
• crystal structure of the HRASLS3-LRAT chimeric enzyme in a thioester catalytic intermediate state revealed a major structural rearrangement accompanied by three-dimensional domain swapping dimerization not observed in native HRASLS (PMID:25383759)
• the flexible main loop of H-REV107, but not that of TIG3, is critical for its NTD to modulate its CTD in inducing cell death. (PMID:25871522)
• Results show that osteosarcoma patients with metastasis showed higher expression of PLA2G16 at both the mRNA and protein levels and shorter overall survival suggesting it as significant prognostic factor for poor outcome. (PMID:25993412)
• suggest a novel regulatory mechanism for peroxisome biogenesis through the interaction between Pex19p and PLA/AT-3 (PMID:26018079)
• our results revealed that H-rev107 is also involved in lipid accumulation in liver cells through the POR pathway via its PLA2 activity. (PMID:26381418)
• Demonstrate increased PLA2G16 expression activates the MAPK pathway to enhance osteosarcoma metastasis. (PMID:26933804)
• study uncovers two competing processes triggered by Picornaviridae virus entry: activation of a pore-activated clearance pathway and recruitment of a PLA2G16 phospholipase to enable genome release (PMID:28077878)
• PLA2G16 SNPs are associated with the colorectal cancer risk in the Chinese population. (PMID:30343388)
• PLA2G16 methylation defines an extensive field defect in histologically normal prostate tissue associated with PC. (PMID:31233548)
• Skeletal muscle expression of adipose-specific phospholipase in peripheral artery disease. (PMID:32853041)
• PLA2G16 is a mutant p53/KLF5 transcriptional target and promotes glycolysis of pancreatic cancer. (PMID:32985124)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	lratb.2	ENSDARG00000077652
mus_musculus	Plaat3	ENSMUSG00000060675
rattus_norvegicus	Plaat3	ENSRNOG00000021206

Paralogs (7): LRAT (ENSG00000121207), PLAAT1 (ENSG00000127252), PLAAT4 (ENSG00000133321), PLAAT2 (ENSG00000133328), LRATD1 (ENSG00000162981), PLAAT5 (ENSG00000168004), LRATD2 (ENSG00000168672)

Protein

Protein identifiers

Phospholipase A and acyltransferase 3 — P53816 (reviewed: P53816)

Alternative names: Adipose-specific phospholipase A2, Group XVI phospholipase A1/A2, H-rev 107 protein homolog, HRAS-like suppressor 1, HRAS-like suppressor 3, HREV107-3, Renal carcinoma antigen NY-REN-65

All UniProt accessions (2): P53816, F5H7E5

UniProt curated annotations — full annotation on UniProt →

Function. Exhibits both phospholipase A1/2 and acyltransferase activities. Shows phospholipase A1 (PLA1) and A2 (PLA2) activity, catalyzing the calcium-independent release of fatty acids from the sn-1 or sn-2 position of glycerophospholipids. For most substrates, PLA1 activity is much higher than PLA2 activity. Shows O-acyltransferase activity,catalyzing the transfer of a fatty acyl group from glycerophospholipid to the hydroxyl group of lysophospholipid. Shows N-acyltransferase activity, catalyzing the calcium-independent transfer of a fatty acyl group at the sn-1 position of phosphatidylcholine (PC) and other glycerophospholipids to the primary amine of phosphatidylethanolamine (PE), forming N-acylphosphatidylethanolamine (NAPE), which serves as precursor for N-acylethanolamines (NAEs). Exhibits high N-acyltransferase activity and low phospholipase A1/2 activity. Required for complete organelle rupture and degradation that occur during eye lens terminal differentiation, when fiber cells that compose the lens degrade all membrane-bound organelles in order to provide lens with transparency to allow the passage of light. Organelle membrane degradation is probably catalyzed by the phospholipase activity. (Microbial infection) Acts as a host factor for picornaviruses: required during early infection to promote viral genome release into the cytoplasm. May act as a cellular sensor of membrane damage at sites of virus entry, which relocalizes to sites of membrane rupture upon virus unfection. Facilitates safe passage of the RNA away from LGALS8, enabling viral genome translation by host ribosome. May also be involved in initiating pore formation, increasing pore size or in maintaining pores for genome delivery. The lipid-modifying enzyme activity is required for this process.

Subunit / interactions. Interacts with PPP2R1A; this interaction might decrease PP2A activity.

Subcellular location. Cell membrane. Cytoplasm. Cytosol. Perinuclear region. Peroxisome membrane. Mitochondrion membrane. Nucleus envelope. Lysosome membrane. Endoplasmic reticulum membrane.

Tissue specificity. Widely expressed. Low expression, if any, in hematopoietic cells and thymus. In testis, confined to round spermatids. Expressed in normal ovarian epithelial cells. Down-regulated in some ovarian carcinomas and testicular germ cell tumors. Highly expressed in white adipose tissue.

Disease relevance. Lipodystrophy, familial partial, 9 (FPLD9) [MIM:620683] An autosomal recessive form of partial lipodystrophy, a disorder characterized by abnormal subcutaneous fat distribution. FPLD9 patients are lean and show muscular hypertrophy, insulin-resistant diabetes with hyperinsulinemia, hypertriglyceridemia with low high-density lipoprotein (HDL) cholesterol, liver steatosis, and polycystic ovary syndrome with hirsutism. Some patients have more generalized lipoatrophy, whereas others have abnormal fat accumulation in the face and neck regions and show cushingoid or acromegalic facial features. Most patients also have neurologic features, including demyelinating polyneuropathy, developmental delay and intellectual disability. The disease is caused by variants affecting the gene represented in this entry.

Domain organisation. The C-terminal transmembrane domain is required for the targeting of the protein to damaged organelles.

Induction. By IFNG and IRF1.

Similarity. Belongs to the H-rev107 family.

RefSeq proteins (2): NP_001121675, NP_009000 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR007053	LRAT_dom	Domain
IPR051496	H-rev107_PLA/AT	Family

Pfam: PF04970

Catalyzed reactions (Rhea), 12 shown:

• a 1,2-diacyl-sn-glycero-3-phosphocholine + H2O = a 1-acyl-sn-glycero-3-phosphocholine + a fatty acid + H(+) (RHEA:15801)
• a 1,2-diacyl-sn-glycero-3-phosphocholine + H2O = a 2-acyl-sn-glycero-3-phosphocholine + a fatty acid + H(+) (RHEA:18689)
• 1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphocholine + H2O = 1-hexadecanoyl-sn-glycero-3-phosphocholine + (9Z)-octadecenoate + H(+) (RHEA:38779)
• 1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphocholine + H2O = 2-(9Z-octadecenoyl)-sn-glycero-3-phosphocholine + hexadecanoate + H(+) (RHEA:38783)
• 1-hexadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-3-phosphocholine + H2O = 1-hexadecanoyl-sn-glycero-3-phosphocholine + (5Z,8Z,11Z,14Z)-eicosatetraenoate + H(+) (RHEA:40427)
• 1-hexadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-3-phosphoethanolamine + H2O = 1-hexadecanoyl-sn-glycero-3-phosphoethanolamine + (5Z,8Z,11Z,14Z)-eicosatetraenoate + H(+) (RHEA:40431)
• 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine + H2O = 2-hexadecanoyl-sn-glycero-3-phosphocholine + hexadecanoate + H(+) (RHEA:40487)
• 1-hexadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-3-phosphocholine + H2O = 2-(5Z,8Z,11Z,14Z)-eicosatetraenoyl-sn-glycero-3-phosphocholine + hexadecanoate + H(+) (RHEA:40571)
• 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine + H2O = (9Z,12Z)-octadecadienoate + 1-hexadecanoyl-sn-glycero-3-phosphocholine + H(+) (RHEA:40811)
• 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphoethanolamine + H2O = 1-hexadecanoyl-sn-glycero-3-phosphoethanolamine + (9Z,12Z)-octadecadienoate + H(+) (RHEA:40815)
• 1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphocholine + H2O = 1-(9Z-octadecenoyl)-sn-glycero-3-phosphocholine + (9Z)-octadecenoate + H(+) (RHEA:40923)
• 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine + H2O = 2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine + hexadecanoate + H(+) (RHEA:40971)

UniProt features (27 total): strand 8, helix 4, mutagenesis site 3, active site 3, topological domain 2, turn 2, chain 1, sequence conflict 1, transmembrane region 1, domain 1, sequence variant 1

Structure

Experimental structures (PDB)

7 structures.

PDB	Method	Resolution (Å)
7ZOM	X-RAY DIFFRACTION	1.6
7C3Z	X-RAY DIFFRACTION	1.96
4DOT	X-RAY DIFFRACTION	1.96
4Q95	X-RAY DIFFRACTION	2.2
7C41	X-RAY DIFFRACTION	2.28
4FA0	X-RAY DIFFRACTION	2.65
2KYT	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P53816-F1	77.12	0.56

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (3): 23; 35; 113 (acyl-thioester intermediate)

Mutagenesis-validated functional residues (3):

Position	Phenotype
39–57	induces a major structural rearrangement accompanied by domain-swapping dimerization and changes in substrate-specificit
113	no effect on ppp2r1a-binding. impaired ability to act as a host factor for picornaviruses.
23	no effect on ppp2r1a-binding.

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-1482788	Acyl chain remodelling of PC
R-HSA-1482801	Acyl chain remodelling of PS
R-HSA-1482839	Acyl chain remodelling of PE
R-HSA-1482922	Acyl chain remodelling of PI

MSigDB gene sets: 451 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_BRAIN_TUMORAL_MACROPHAGE_UP, GSE18804_SPLEEN_MACROPHAGE_VS_TUMORAL_MACROPHAGE_UP, GSE18804_SPLEEN_MACROPHAGE_VS_COLON_TUMORAL_MACROPHAGE_DN, GOBP_LENS_FIBER_CELL_DIFFERENTIATION, GOBP_EPITHELIUM_DEVELOPMENT, GOBP_PHOSPHOLIPID_METABOLIC_PROCESS, GOBP_PHOSPHATIDYLCHOLINE_METABOLIC_PROCESS, GOCC_VACUOLAR_MEMBRANE, GOBP_MEMBRANE_DISASSEMBLY, GOZGIT_ESR1_TARGETS_DN, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_UP, ACEVEDO_NORMAL_TISSUE_ADJACENT_TO_LIVER_TUMOR_DN, GOBP_ORGANOPHOSPHATE_METABOLIC_PROCESS, chr11q13

GO Biological Process (14): triglyceride metabolic process (GO:0006641), phospholipid metabolic process (GO:0006644), peroxisome organization (GO:0007031), phospholipid biosynthetic process (GO:0008654), response to bacterium (GO:0009617), lipid catabolic process (GO:0016042), membrane disassembly (GO:0030397), phosphatidylethanolamine acyl-chain remodeling (GO:0036152), ether lipid metabolic process (GO:0046485), N-acylphosphatidylethanolamine metabolic process (GO:0070292), lens fiber cell differentiation (GO:0070306), organelle disassembly (GO:1903008), regulation of adipose tissue development (GO:1904177), lipid metabolic process (GO:0006629)

GO Molecular Function (9): A2-type glycerophospholipase activity (GO:0004623), lipid binding (GO:0008289), glycerophospholipid phospholipase A1 activity (GO:0008970), obsolete N-acyltransferase activity (GO:0016410), acyltransferase activity (GO:0016746), glycerophospholipase activity (GO:0004620), protein binding (GO:0005515), transferase activity (GO:0016740), hydrolase activity (GO:0016787)

GO Cellular Component (15): nuclear envelope (GO:0005635), cytoplasm (GO:0005737), mitochondrion (GO:0005739), lysosome (GO:0005764), lysosomal membrane (GO:0005765), peroxisome (GO:0005777), peroxisomal membrane (GO:0005778), endoplasmic reticulum (GO:0005783), endoplasmic reticulum membrane (GO:0005789), cytosol (GO:0005829), plasma membrane (GO:0005886), mitochondrial membrane (GO:0031966), perinuclear region of cytoplasm (GO:0048471), nucleus (GO:0005634), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Glycerophospholipid biosynthesis	4

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
cytoplasm	4
lipid metabolic process	3
intracellular membrane-bounded organelle	3
organelle organization	2
cellular component disassembly	2
binding	2
catalytic activity	2
endomembrane system	2
organelle membrane	2
acylglycerol metabolic process	1
organophosphate metabolic process	1
phospholipid metabolic process	1
lipid biosynthetic process	1
organophosphate biosynthetic process	1
response to other organism	1
catabolic process	1
membrane organization	1
phosphatidylcholine metabolic process	1
phosphatidylethanolamine metabolic process	1
lens development in camera-type eye	1
epithelial cell differentiation	1
regulation of developmental process	1
adipose tissue development	1
primary metabolic process	1
glycerophospholipase activity	1
carboxylic ester hydrolase activity	1
A1-type glycerophospholipase activity	1
transferase activity	1
phospholipase activity	1
nucleus	1
organelle envelope	1
intracellular anatomical structure	1
lytic vacuole	1
lysosome	1
lytic vacuole membrane	1
microbody	1
peroxisome	1
microbody membrane	1
nuclear outer membrane-endoplasmic reticulum membrane network	1

Protein interactions and networks

STRING

2908 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PLAAT3	CRABP2	P29373	747
PLAAT3	RARG	P13631	642
PLAAT3	PLA2G15	Q8NCC3	640
PLAAT3	PLA2G2A	P14555	582
PLAAT3	SETD3	Q86TU7	563
PLAAT3	RARB	P10826	553
PLAAT3	PEX19	P40855	543
PLAAT3	PLA2G4A	P47712	528
PLAAT3	PLA2G3	Q9NZ20	499
PLAAT3	PLA2G2D	Q9UNK4	496
PLAAT3	PLA2G10	O15496	490
PLAAT3	PLA2G6	O60733	488
PLAAT3	KRAS	P01116	485
PLAAT3	PLA2G5	P39877	483
PLAAT3	ENPP2	Q13822	472

IntAct

26 interactions, top by confidence:

A	B	Type	Score
UBQLN1	PLAAT3	psi-mi:“MI:0915”(physical association)	0.780
PLAAT3	UBQLN1	psi-mi:“MI:0915”(physical association)	0.780
PPP2R1A	PLAAT3	psi-mi:“MI:0915”(physical association)	0.640
PLAAT3	PPP2R1A	psi-mi:“MI:0915”(physical association)	0.640
PLAAT3	PPP2R1A	psi-mi:“MI:0403”(colocalization)	0.640
PLAAT3	UBQLN1	psi-mi:“MI:0915”(physical association)	0.560
UBQLN1	PLAAT3	psi-mi:“MI:0915”(physical association)	0.560
PLAAT3	UBQLN2	psi-mi:“MI:0915”(physical association)	0.560
PLAAT3	OCLN	psi-mi:“MI:0914”(association)	0.350
PRKCSH	KLRG2	psi-mi:“MI:0914”(association)	0.350
MFSD14A	FAM171A2	psi-mi:“MI:0914”(association)	0.350
PLAAT3	UBQLN2	psi-mi:“MI:0915”(physical association)	0.000
PLAAT3	UBQLN1	psi-mi:“MI:0915”(physical association)	0.000
NRIP1	PLAAT3	psi-mi:“MI:0915”(physical association)	0.000
PLAAT3	UBQLN4	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (19): UBQLN1 (Two-hybrid), UBQLN1 (Two-hybrid), HRAS (Affinity Capture-Western), PLA2G16 (Affinity Capture-Western), PLA2G16 (Affinity Capture-MS), PLA2G16 (Two-hybrid), UBQLN2 (Two-hybrid), OCLN (Affinity Capture-MS), MIB2 (Affinity Capture-MS), PLA2G16 (Affinity Capture-MS), PLA2G16 (Two-hybrid), PLA2G16 (Affinity Capture-MS), PLA2G16 (Affinity Capture-MS), PLA2G16 (Affinity Capture-RNA), PLA2G16 (Two-hybrid)

ESM2 similar proteins: A0A0R4IY06, B8BKI7, D2KX21, D3ZLY0, E0CSI1, O54909, O75452, O88451, P00860, P09057, P11926, P14019, P17516, P27117, P27118, P27119, P27120, P50170, P53816, P53817, P55006, P70694, P97872, Q04799, Q1XAA8, Q2R483, Q3T067, Q3UFY7, Q571F8, Q5R611, Q6AY30, Q6AYP7, Q6P4H8, Q86TW2, Q86V88, Q8R127, Q8R2J9, Q8R3U1, Q8VDG3, Q93V51

Diamond homologs: A0A0R4IY06, D2KX21, P53816, P53817, Q4KLN5, Q5R611, Q8R3U1, Q96KN8, Q9BGL2, Q9CPX5, Q9HDD0, Q9JI61, Q9NWW9, Q9QZU4, Q9UL19, O95237, Q9JI60, Q3ZCA1, Q96KN1, Q96KN4, Q9D650

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
PLAAT3	down-regulates	PPP2CA
PLAAT3	down-regulates	PPP2CB

Disease & clinical

Clinical variants and AI predictions

ClinVar

51 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	3
Likely pathogenic	1
Uncertain significance	38
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (4)

Variant ID	HGVS	Classification
2691740	NM_001128203.2(PLAAT3):c.16-4823_118+167del	Pathogenic
2691741	NM_001128203.2(PLAAT3):c.286dup (p.Ala96fs)	Pathogenic
2691742	NM_001128203.2(PLAAT3):c.339C>A (p.Cys113Ter)	Pathogenic
4845839	NM_001128203.2(PLAAT3):c.387+2T>C	Likely pathogenic

SpliceAI

655 predictions. Top by Δscore:

Variant	Effect	Δscore
11:63575044:GACCT:G	acceptor_loss	1.0000
11:63575046:CCT:C	acceptor_loss	1.0000
11:63575047:CT:C	acceptor_loss	1.0000
11:63575048:T:A	acceptor_loss	1.0000
11:63590095:CGCA:C	donor_loss	1.0000
11:63590096:GCACC:G	donor_loss	1.0000
11:63590097:CAC:C	donor_loss	1.0000
11:63590378:C:CT	acceptor_gain	1.0000
11:63598059:A:AC	donor_gain	1.0000
11:63598060:C:CC	donor_gain	1.0000
11:63613998:A:AC	donor_gain	1.0000
11:63613999:C:CC	donor_gain	1.0000
11:63614018:C:A	donor_gain	1.0000
11:63574901:C:CA	donor_gain	0.9900
11:63590157:A:AC	donor_gain	0.9900
11:63590158:C:CC	donor_gain	0.9900
11:63590364:CTCAC:C	acceptor_gain	0.9900
11:63590365:TCAC:T	acceptor_gain	0.9900
11:63590366:CAC:C	acceptor_gain	0.9900
11:63590366:CACC:C	acceptor_gain	0.9900
11:63590369:C:CA	acceptor_loss	0.9900
11:63590369:C:CC	acceptor_gain	0.9900
11:63590370:T:C	acceptor_loss	0.9900
11:63590378:C:T	acceptor_gain	0.9900
11:63597628:AGATC:A	donor_gain	0.9900
11:63598160:CTGG:C	acceptor_gain	0.9900
11:63598164:C:CC	acceptor_gain	0.9900
11:63613999:CA:C	donor_gain	0.9900
11:63613999:CAA:C	donor_gain	0.9900
11:63613999:CAAT:C	donor_gain	0.9900

AlphaMissense

1058 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
11:63590126:G:T	R121S	0.994
11:63590151:G:C	N112K	0.991
11:63590151:G:T	N112K	0.991
11:63598107:C:A	W24C	0.991
11:63598107:C:G	W24C	0.991
11:63598109:A:G	W24R	0.991
11:63598109:A:T	W24R	0.991
11:63590139:A:C	F116L	0.990
11:63590139:A:T	F116L	0.990
11:63590141:A:G	F116L	0.990
11:63598141:A:G	L13P	0.990
11:63590106:A:C	S127R	0.989
11:63590106:A:T	S127R	0.989
11:63590108:T:G	S127R	0.989
11:63590128:A:G	L120P	0.989
11:63598078:A:T	V34D	0.989
11:63590149:C:T	C113Y	0.988
11:63590308:A:T	V60E	0.987
11:63590125:C:G	R121P	0.986
11:63590140:A:G	F116S	0.985
11:63590146:T:A	E114V	0.985
11:63590150:A:G	C113R	0.985
11:63598106:C:G	A25P	0.985
11:63590145:C:A	E114D	0.984
11:63590145:C:G	E114D	0.984
11:63590148:G:C	C113W	0.984
11:63598074:A:C	H35Q	0.984
11:63598074:A:T	H35Q	0.984
11:63590126:G:C	R121G	0.983
11:63598081:A:T	V33E	0.982

dbSNP variants (sampled 300 via entrez): RS1000036247 (11:63614172 CG>C), RS1000073148 (11:63604260 T>A), RS1000227954 (11:63587678 A>C), RS1000357723 (11:63600804 A>G), RS1000429992 (11:63613913 G>C), RS1000450898 (11:63593125 G>T), RS1000474695 (11:63606153 A>C), RS1000618823 (11:63594676 G>A,C), RS1000813685 (11:63601131 T>C), RS1000816281 (11:63594556 T>C), RS1000845492 (11:63575813 T>TA), RS1000911442 (11:63582372 G>A), RS1000931269 (11:63582578 C>T), RS1000932068 (11:63618759 A>G), RS1001106721 (11:63582639 A>G)

Disease associations

OMIM: gene MIM:613867 | disease phenotypes: MIM:620683

GenCC curated gene-disease

Disease	Classification	Inheritance
lipodystrophy, familial partial, type 9	Strong	Autosomal recessive

Mondo (1): lipodystrophy, familial partial, type 9 (MONDO:0958034)

Orphanet (1): Lipodystrophy-demyelinating peripheral sensory-motor neuropathy syndrome (Orphanet:686999)

HPO phenotypes

49 total (30 of 49 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000147	Polycystic ovaries
HP:0000303	Mandibular prognathia
HP:0000369	Low-set ears
HP:0000444	Convex nasal ridge
HP:0000448	Prominent nose
HP:0000470	Short neck
HP:0000490	Deeply set eye
HP:0000771	Gynecomastia
HP:0000821	Hypothyroidism
HP:0000822	Hypertension
HP:0000826	Precocious puberty
HP:0000831	Insulin-resistant diabetes mellitus
HP:0000842	Hyperinsulinemia
HP:0000956	Acanthosis nigricans
HP:0001007	Hirsutism
HP:0001249	Intellectual disability
HP:0001263	Global developmental delay
HP:0001284	Areflexia
HP:0001397	Hepatic steatosis
HP:0001761	Pes cavus
HP:0001771	Achilles tendon contracture
HP:0002064	Spastic gait
HP:0002076	Migraine
HP:0002155	Hypertriglyceridemia
HP:0002240	Hepatomegaly
HP:0002650	Scoliosis
HP:0002808	Kyphosis
HP:0002829	Arthralgia
HP:0002857	Genu valgum

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3831244 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

33 potent at pChembl≥5 of 33 total, top 33 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.00	IC50	100	nM	CHEMBL4633449
7.00	IC50	100	nM	CHEMBL4639199
6.90	IC50	125.9	nM	CHEMBL4639242
6.80	IC50	158.5	nM	CHEMBL4639478
6.80	IC50	158.5	nM	CHEMBL4649677
6.70	IC50	199.5	nM	CHEMBL4641977
6.60	IC50	251.2	nM	CHEMBL4643099
6.60	IC50	251.2	nM	CHEMBL4643782
6.60	IC50	251.2	nM	CHEMBL4644464
6.60	IC50	251.2	nM	CHEMBL4636806
6.40	IC50	398.1	nM	CHEMBL4645342
6.10	IC50	794.3	nM	CHEMBL4636379
6.00	IC50	1000	nM	CHEMBL4643675
6.00	IC50	1000	nM	CHEMBL4636463
6.00	IC50	1000	nM	CHEMBL4640863
6.00	IC50	1000	nM	CHEMBL4643908
5.90	IC50	1259	nM	CHEMBL4642795
5.80	IC50	1585	nM	CHEMBL4646350
5.80	IC50	1585	nM	CHEMBL4632512
5.80	IC50	1585	nM	CHEMBL4634598
5.80	IC50	1585	nM	CHEMBL4645578
5.70	IC50	1995	nM	CHEMBL4640676
5.70	IC50	1995	nM	CHEMBL4639235
5.70	IC50	1995	nM	CHEMBL4644324
5.60	IC50	2512	nM	CHEMBL4645552
5.60	IC50	2512	nM	CHEMBL4636625
5.50	IC50	3162	nM	CHEMBL4641818
5.50	IC50	3162	nM	CHEMBL4636282
5.40	IC50	3981	nM	CHEMBL4648272
5.30	IC50	5012	nM	CHEMBL4641304
5.30	IC50	5012	nM	CHEMBL4646429
5.10	IC50	7943	nM	CHEMBL4638043
5.10	IC50	7943	nM	CHEMBL4649884

PubChem BioAssay actives

33 with measured affinity, of 57 total; 33 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-(3,4-dichlorophenyl)-2-oxo-N-(2-phenylethyl)butanamide	1666052: Inhibition of full-length C-terminal FLAG-tagged human PLAAT3 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	0.1000	uM
2-oxo-5-phenyl-N-[2-[4-[[5-(trifluoromethyl)-2-pyridinyl]oxy]phenyl]ethyl]pentanamide	1666052: Inhibition of full-length C-terminal FLAG-tagged human PLAAT3 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	0.1000	uM
N-[2-(4-methylphenyl)ethyl]-2-oxo-5-phenylpentanamide	1666052: Inhibition of full-length C-terminal FLAG-tagged human PLAAT3 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	0.1259	uM
N-[2-(4-bromophenyl)ethyl]-2-oxo-5-phenylpentanamide	1666052: Inhibition of full-length C-terminal FLAG-tagged human PLAAT3 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	0.1585	uM
2-oxo-5-phenyl-N-[2-[4-[[6-(trifluoromethyl)-3-pyridinyl]oxy]phenyl]ethyl]pentanamide	1666052: Inhibition of full-length C-terminal FLAG-tagged human PLAAT3 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	0.1585	uM
N-[2-(3-chlorophenyl)ethyl]-2-oxo-5-phenylpentanamide	1666052: Inhibition of full-length C-terminal FLAG-tagged human PLAAT3 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	0.1995	uM
N-[2-[4-(2-chloropyrimidin-4-yl)oxyphenyl]ethyl]-2-oxo-5-phenylpentanamide	1666052: Inhibition of full-length C-terminal FLAG-tagged human PLAAT3 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	0.2512	uM
2-oxo-5-phenyl-N-[2-(4-pyrazin-2-yloxyphenyl)ethyl]pentanamide	1666052: Inhibition of full-length C-terminal FLAG-tagged human PLAAT3 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	0.2512	uM
N-[2-(2,4-dichlorophenyl)ethyl]-2-oxo-5-phenylpentanamide	1666052: Inhibition of full-length C-terminal FLAG-tagged human PLAAT3 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	0.2512	uM
2-oxo-N-[2-(4-phenoxyphenyl)ethyl]-5-phenylpentanamide	1666052: Inhibition of full-length C-terminal FLAG-tagged human PLAAT3 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	0.2512	uM
2-oxo-5-phenyl-N-(2-phenylethyl)pentanamide	1666052: Inhibition of full-length C-terminal FLAG-tagged human PLAAT3 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	0.3981	uM
N-[2-(4-methoxyphenyl)ethyl]-2-oxo-5-phenylpentanamide	1666052: Inhibition of full-length C-terminal FLAG-tagged human PLAAT3 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	0.7943	uM
4-(4-chlorophenyl)-2-oxo-N-(4-phenylbutyl)butanamide	1666052: Inhibition of full-length C-terminal FLAG-tagged human PLAAT3 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	1.0000	uM
2-oxo-6-phenyl-N-(2-phenylethyl)hexanamide	1666052: Inhibition of full-length C-terminal FLAG-tagged human PLAAT3 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	1.0000	uM
4-(4-chlorophenyl)-2-oxo-N-(2-phenylethyl)butanamide	1666052: Inhibition of full-length C-terminal FLAG-tagged human PLAAT3 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	1.0000	uM
N-[2-(3,4-dimethoxyphenyl)ethyl]-2-oxo-5-phenylpentanamide	1666052: Inhibition of full-length C-terminal FLAG-tagged human PLAAT3 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	1.0000	uM
N-[2-(2-chlorophenyl)ethyl]-2-oxo-5-phenylpentanamide	1666052: Inhibition of full-length C-terminal FLAG-tagged human PLAAT3 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	1.2589	uM
(E)-2-oxo-4-phenyl-N-(2-phenylethyl)but-3-enamide	1666052: Inhibition of full-length C-terminal FLAG-tagged human PLAAT3 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	1.5849	uM
4-(3-chlorophenyl)-2-oxo-N-(2-phenylethyl)butanamide	1666052: Inhibition of full-length C-terminal FLAG-tagged human PLAAT3 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	1.5849	uM
N-[2-(4-hydroxyphenyl)ethyl]-2-oxo-5-phenylpentanamide	1666052: Inhibition of full-length C-terminal FLAG-tagged human PLAAT3 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	1.5849	uM
N-benzyl-4-(4-chlorophenyl)-2-oxobutanamide	1666052: Inhibition of full-length C-terminal FLAG-tagged human PLAAT3 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	1.5849	uM
4-(2-chlorophenyl)-2-oxo-N-(2-phenylethyl)butanamide	1666052: Inhibition of full-length C-terminal FLAG-tagged human PLAAT3 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	1.9953	uM
4-(4-methylphenyl)-2-oxo-N-(2-phenylethyl)butanamide	1666052: Inhibition of full-length C-terminal FLAG-tagged human PLAAT3 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	1.9953	uM
2-oxo-5-phenyl-N-[2-(4-pyrimidin-2-yloxyphenyl)ethyl]pentanamide	1666052: Inhibition of full-length C-terminal FLAG-tagged human PLAAT3 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	1.9953	uM
(E)-4-(4-bromophenyl)-2-oxo-N-(2-phenylethyl)but-3-enamide	1666052: Inhibition of full-length C-terminal FLAG-tagged human PLAAT3 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	2.5119	uM
(E)-4-(4-chlorophenyl)-2-oxo-N-(2-phenylethyl)but-3-enamide	1666052: Inhibition of full-length C-terminal FLAG-tagged human PLAAT3 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	2.5119	uM
(E)-2-oxo-N-(2-phenylethyl)-4-(3-phenylphenyl)but-3-enamide	1666052: Inhibition of full-length C-terminal FLAG-tagged human PLAAT3 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	3.1623	uM
4-(4-methoxyphenyl)-2-oxo-N-(2-phenylethyl)butanamide	1666052: Inhibition of full-length C-terminal FLAG-tagged human PLAAT3 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	3.1623	uM
2-oxo-4-(4-phenoxyphenyl)-N-(2-phenylethyl)butanamide	1666052: Inhibition of full-length C-terminal FLAG-tagged human PLAAT3 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	3.9811	uM
4-(4-fluorophenyl)-2-oxo-N-(2-phenylethyl)butanamide	1666052: Inhibition of full-length C-terminal FLAG-tagged human PLAAT3 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	5.0119	uM
(E)-4-(4-methoxyphenyl)-2-oxo-N-(2-phenylethyl)but-3-enamide	1666052: Inhibition of full-length C-terminal FLAG-tagged human PLAAT3 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	5.0119	uM
4-(4-chlorophenyl)-N-ethyl-2-oxobutanamide	1666052: Inhibition of full-length C-terminal FLAG-tagged human PLAAT3 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	7.9433	uM
2-oxo-N-(2-phenylethyl)-4-[4-(trifluoromethyl)phenyl]butanamide	1666052: Inhibition of full-length C-terminal FLAG-tagged human PLAAT3 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	7.9433	uM

CTD chemical–gene interactions

48 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression	6
sodium arsenite	affects expression, decreases expression, increases expression	5
Tetrachlorodibenzodioxin	increases expression	3
Cadmium Chloride	decreases expression, increases abundance, increases expression	3
nickel sulfate	increases expression	2
entinostat	increases expression, affects cotreatment	2
Benzo(a)pyrene	decreases expression, increases expression	2
Cisplatin	affects expression, affects cotreatment, increases expression	2
Dexamethasone	increases expression, affects cotreatment	2
Quercetin	affects cotreatment, increases expression	2
Cyclosporine	decreases expression	2
3,19-(2-bromobenzylidene)andrographolide	decreases response to substance, increases expression	1
bisphenol F	affects cotreatment, increases expression	1
dicrotophos	decreases expression	1
potassium perchlorate	decreases expression	1
sodium arsenate	decreases expression	1
arsenite	affects binding, increases reaction	1
mono-(2-ethylhexyl)phthalate	increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
S-(1,2-dichlorovinyl)cysteine	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	increases expression, affects cotreatment	1
belinostat	affects cotreatment, increases expression	1
ICG 001	increases expression	1
Grape Seed Proanthocyanidins	decreases expression, affects cotreatment	1
dorsomorphin	affects cotreatment, increases expression	1
jinfukang	affects cotreatment, increases expression	1
Temozolomide	increases expression	1
Decitabine	affects expression	1
Acetaminophen	decreases expression	1
Ascorbic Acid	affects cotreatment, increases expression	1

ChEMBL screening assays

2 unique, capped per target: 2 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4626913	Binding	Inhibition of full-length C-terminal FLAG-tagged human PLAAT3 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	Structure-Activity Relationship Studies of α-Ketoamides as Inhibitors of the Phospholipase A and Acyltransferase Enzyme Family. — J Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.